Protocol to Monitor the Neurological Development of Infants With Exposure in Utero From Birth to 15 Months in Tanezumab Clinical Studies
Clinical trial NCT03031938 · COMPLETED
Trial details
- NCT number
- NCT03031938
- Sponsor
- Pfizer
- Status
- COMPLETED
- Phase
- Phase 3
- Study type
- INTERVENTIONAL
- Start date
- 2017-11-03
- Primary completion
- 2020-06-04
- Enrollment
- 4
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.